In conclusion, these data suggest that these 9 proteins that are unaffected by glucose variability may constitute a focused biomarker panel, useful for assessing β-cell dysfunction in T2D that may facilitate future clinical decision-making on insulin therapy initiation. The gene discussed is INS; the disease is type 2 diabetes mellitus.